Mostrar el registro sencillo del ítem

dc.contributor.author
Esteban, Ignacio  
dc.contributor.author
Bergero, Georgina  
dc.contributor.author
Alves, Camila  
dc.contributor.author
Bronstein, Micaela  
dc.contributor.author
Ziegler, Valeria  
dc.contributor.author
Wood, Cristian  
dc.contributor.author
Caballero, Mauricio Tomás  
dc.contributor.author
Wappner, Diego  
dc.contributor.author
Libster, Romina Paula  
dc.contributor.author
Perez Marc, Gonzalo  
dc.contributor.author
Polack, Fernando Pedro  
dc.date.available
2022-02-02T12:01:02Z  
dc.date.issued
2021-08  
dc.identifier.citation
Esteban, Ignacio; Bergero, Georgina; Alves, Camila; Bronstein, Micaela; Ziegler, Valeria; et al.; Asymptomatic COVID-19 in the elderly: dementia and viral clearance as risk factors for disease progression; Bill & Melinda Gates Foundation; Gates Open Research; 5; 8-2021; 1-8  
dc.identifier.issn
2572-4754  
dc.identifier.uri
http://hdl.handle.net/11336/151159  
dc.description.abstract
Background:SARS-CoV-2 infected individuals ≥60 years old have the highest hospitalization rates and represent >80% fatalities. Within this population, those in long-term facilities represent >50% of the total COVID-19 related deaths per country. Among those without symptoms, the rate of pre-symptomatic illness is unclear, and potential predictors of progression for symptom development are unknown.Our objective was to delineate the natural evolution of asymptomatic SARS-CoV-2 infection in elders and identify determinants of progression.Methods:We established a medical surveillance team monitoring 63 geriatric institutions. When an index COVID-19 case emerged, we tested all other eligible asymptomatic elders ≥75 or >60 years old with at least 1 comorbidity. SARS-CoV-2 infected elders were followed for 28 days. Disease was diagnosed when any COVID-19 manifestation occurred. SARS-CoV-2 load at enrollment, shedding on day 15, and antibody responses were also studied.Results:After 28 days of follow-up, 74/113(65%) SARS-CoV-2-infected elders remained asymptomatic. 21/39(54%) pre-symptomatic patients developed hypoxemia and ten pre-symptomatic patients died(median day 13.5,IQR 12).Dementia was the only clinical risk factor associated with disease(OR 2.41(95%CI=1.08, 5.39). In a multivariable logistic regression model, dementia remained as a risk factor for COVID-19 severe disease. Furthermore, dementia status showed a statistically significant different trend when assessing the cumulative probability of developing COVID-19 symptoms(log-rank p=0.027).On day 15, SARS-CoV-2 was detectable in 30% of the asymptomatic group while in 61% of the pre-symptomatic(p=0.012).No differences were observed among groups in RT-PCR mean cycle threshold at enrollment(p=0.391) and in the rates of antibody seropositivity(IgM and IgG against SARS-CoV-2 nucleocapsid protein).Conclusions:In summary, 2/3 of our cohort of SARS-CoV-2 infected elders from vulnerable communities in Argentina remained asymptomatic after 28 days of follow-up with high mortality among those developing symptoms. Dementia and persistent SARS-CoV-2 shedding were associated with progression from asymptomatic to symptomatic infection.  
dc.format
application/pdf  
dc.language.iso
eng  
dc.publisher
Bill & Melinda Gates Foundation  
dc.rights
info:eu-repo/semantics/openAccess  
dc.rights.uri
https://creativecommons.org/licenses/by-nc-sa/2.5/ar/  
dc.subject
SARS COV2  
dc.subject
COVID-19  
dc.subject
DEMENTIA  
dc.subject.classification
Epidemiología  
dc.subject.classification
Ciencias de la Salud  
dc.subject.classification
CIENCIAS MÉDICAS Y DE LA SALUD  
dc.title
Asymptomatic COVID-19 in the elderly: dementia and viral clearance as risk factors for disease progression  
dc.type
info:eu-repo/semantics/article  
dc.type
info:ar-repo/semantics/artículo  
dc.type
info:eu-repo/semantics/publishedVersion  
dc.date.updated
2022-02-01T17:41:13Z  
dc.journal.volume
5  
dc.journal.pagination
1-8  
dc.journal.pais
Estados Unidos  
dc.description.fil
Fil: Esteban, Ignacio. Fundación para la Investigación en Infectología Infantil; Argentina  
dc.description.fil
Fil: Bergero, Georgina. Fundación para la Investigación en Infectología Infantil; Argentina  
dc.description.fil
Fil: Alves, Camila. Fundación para la Investigación en Infectología Infantil; Argentina  
dc.description.fil
Fil: Bronstein, Micaela. Fundación para la Investigación en Infectología Infantil; Argentina  
dc.description.fil
Fil: Ziegler, Valeria. Fundación para la Investigación en Infectología Infantil; Argentina  
dc.description.fil
Fil: Wood, Cristian. Ministerio de Defensa. Ejército Argentino. Hospital Militar Central Cirujano Mayor "Dr. Cosme Argerich"; Argentina  
dc.description.fil
Fil: Caballero, Mauricio Tomás. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina. Fundación para la Investigación en Infectología Infantil; Argentina  
dc.description.fil
Fil: Wappner, Diego. No especifíca;  
dc.description.fil
Fil: Libster, Romina Paula. Fundación para la Investigación en Infectología Infantil; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina  
dc.description.fil
Fil: Perez Marc, Gonzalo. Ministerio de Defensa. Ejército Argentino. Hospital Militar Central Cirujano Mayor "Dr. Cosme Argerich"; Argentina  
dc.description.fil
Fil: Polack, Fernando Pedro. Fundación para la Investigación en Infectología Infantil; Argentina  
dc.journal.title
Gates Open Research  
dc.relation.alternativeid
info:eu-repo/semantics/altIdentifier/url/https://gatesopenresearch.org/articles/5-143/v1  
dc.relation.alternativeid
info:eu-repo/semantics/altIdentifier/doi/http://dx.doi.org/10.12688/gatesopenres.13357.1